2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

1489 Genome-wide CRISPR/Cas9 screening identifies novel genetic drivers of gemtuzumab ozogamicin resistance in acute myeloid leukemia

Aneesha Nath, POST DOCTORAL FELLOW, Phani Krishna Parcha, PhD2, Abderrahmane Tagmount3, Christopher Vulpe, PRPOFESSOR4, Jatinder K Lamba, PhD5
1 University of Florida, Gainesville, Florida, United States
2 University of Florida, Gainesville, Florida, United States
3 University of Florida, Gainesville, Florida, United States
4 University of Florida, Gainesville, Florida, United States
5 University of Florida, Gainesville, Florida, United States

Introduction: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with poor clinical outcomes. CD33 is expressed in approximately 85–90% of AML cases, making it an attractive therapeutic target. Gemtuzumab ozogamicin (GO), the only FDA-approved CD33-directed antibody-drug conjugate for AML, improves outcomes in patients with newly diagnosed or relapsed/refractory CD33-positive AML; however, intrinsic and acquired resistance remain major barriers to its long-term efficacy. Although resistance has been associated with impaired CD33 internalization and reduced CD33 expression, additional genetic determinants remain poorly defined. Here, we combined genome-wide CRISPR/Cas9 functional screening with clinical outcome analyses to identify novel regulators of GO response.

Methods: Genome-wide CRISPR/Cas9 knockout screens targeting approximately 19,000 genes were performed in the CD33-positive AML cell lines OCI-AML3 and MV4-11. Following puromycin selection, cells were treated with GO and cultured for approximately seven population doublings. Genomic DNA was collected at two independent time points, sgRNA abundance was quantified by Illumina NovaSeq X Plus sequencing, and enriched or depleted sgRNAs were identified using the MAGeCK robust rank aggregation (RRA) algorithm. Genes were classified as mediators of GO resistance or sensitivity using a ±1.5 standard deviation cutoff from the mean RRA score. Candidate resistance genes were subsequently integrated with transcriptomic and clinical outcome data from patients enrolled in the Children's Oncology Group AAML0531 trial.

Results: Genome-wide CRISPR screening identified 110 shared resistance genes and 77 shared sensitivity genes across OCI-AML3 and MV4-11 cells, demonstrating a high degree of concordance between independent AML models. Integration of resistance-associated genes with AAML0531 transcriptomic and clinical data prioritized 10 genes whose elevated expression was associated with adverse clinical outcomes, including minimal residual disease after induction 1 (MRD1), event-free survival (EFS), and overall survival (OS). These genes included transcriptional regulators (BCL11A, ID2, ZNF28, ZNF248, ZC2HC1A), RNA metabolism genes (METTL6 and WDR75), the DNA repair gene PMS1, the intracellular transport gene DYNLT3, and the poorly characterized gene SMKR1.

Consistent with our CRISPR findings, elevated expression of BCL11A and ID2 has previously been associated with inferior remission rates, increased relapse risk, and chemotherapy resistance in AML, supporting the validity of our screening approach. In contrast, several prioritized candidates, including ZNF28, ZNF248, ZC2HC1A, WDR75, DYNLT3, and SMKR1, have not previously been implicated in GO response. Multivariable analyses adjusting for established clinical prognostic factors demonstrated that elevated WDR75 expression was independently associated with inferior EFS (HR = 2.3.X, P = 0.002) and OS (HR = 2.1, P = 0.03), while elevated ZNF248 expression independently predicted inferior EFS (HR = 1.8, P = 0.025). These findings identify novel candidate mediators of GO resistance with both functional and clinical relevance.

Conclusion: By integrating genome-wide CRISPR functional genomics with clinical outcome data, we identified previously unrecognized genetic determinants of GO resistance in AML. Beyond established factors, our study highlights WDR75 (ribosome biogenesis factor) and ZNF248, together with several other novel candidates, as potential biomarkers of GO response and therapeutic vulnerabilities. These findings provide a functional framework for understanding GO resistance and establish a foundation for future mechanistic studies and the development of rational combination strategies to improve the efficacy of CD33-directed therapy.

 

Aneesha Nath, POST DOCTORAL FELLOW: No relevant conflicts of interest to declare.